Duchenne Muscular Dystrophy Therapeutics Market

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne?a mutation in the DMD gene?happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Duchenne Muscular Dystrophy Therapeutics Market contains market size and forecasts of Duchenne Muscular Dystrophy (DMD) Therapeutics in Global, including the following market information:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Duchenne Muscular Dystrophy (DMD) Therapeutics market was valued at 1367.7 million in 2021 and is projected to reach US$ 14630 million by 2028, at a CAGR of 40.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Exondys Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco and Santhera Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Percentages, by Type, 2021 (%)

Exondys

Emflaza

Translarna

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Home Care

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Duchenne Muscular Dystrophy (DMD) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Duchenne Muscular Dystrophy (DMD) Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals